Sustained glycemic control and less hypoglycemia with new insulin glargine 300 U/mL vs. 100 U/mL: 1-year results in T2DM with basal+mealtime insulin (EDITION 1)

Background and aims: EDITION 1 studied the efficacy and safety of new insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with T2DM using basal plus mealtime insulin. Materials and methods: In EDITION 1, people (N = 807) with elevated HbA1c were randomized to titrate Gla-300 or Gla-100 once daily in the evening for 6 months while continuing mealtime insulin. In a 6-month open-label extension, participants continued Gla-300 or Gla-100; 89% and 88% completed 12 months' treatment. Results: Improved glycemic control was maintained over 12 months in both groups (LS mean difference Gla-300…